VRDN Quote, Financials, Valuation and Earnings

Electromed, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of 12.65%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Electromed, Inc.'s return on equity of 18.89%.

Viridian Therapeutics, Inc. has a consensus price target of $39.81, signalling upside risk potential of 28.23%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 29.45%. Given that Electromed, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Electromed, Inc. is more attractive than Viridian Therapeutics, Inc..

Viridian Therapeutics, Inc. has a beta of 0.914, which suggesting that the stock is 8.612% less volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.

Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.

Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are larger than Electromed, Inc. quarterly revenues of $16.9M. Viridian Therapeutics, Inc.'s net income of -$34.6M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 29.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 36.73x versus 3.71x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Orthofix Medical, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of -11.09%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Orthofix Medical, Inc.'s return on equity of -24.94%.

Viridian Therapeutics, Inc. has a consensus price target of $39.81, signalling upside risk potential of 28.23%. On the other hand Orthofix Medical, Inc. has an analysts' consensus of $22.80 which suggests that it could grow by 41.82%. Given that Orthofix Medical, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Orthofix Medical, Inc. is more attractive than Viridian Therapeutics, Inc..

Viridian Therapeutics, Inc. has a beta of 0.914, which suggesting that the stock is 8.612% less volatile than S&P 500. In comparison Orthofix Medical, Inc. has a beta of 0.819, suggesting its less volatile than the S&P 500 by 18.057%.

Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orthofix Medical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Orthofix Medical, Inc. pays out -- of its earnings as a dividend.

Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are smaller than Orthofix Medical, Inc. quarterly revenues of $205.6M. Viridian Therapeutics, Inc.'s net income of -$34.6M is lower than Orthofix Medical, Inc.'s net income of -$22.8M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Orthofix Medical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 36.73x versus 0.76x for Orthofix Medical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of -862.39%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat VolitionRX Ltd.'s return on equity of --.

Viridian Therapeutics, Inc. has a consensus price target of $39.81, signalling upside risk potential of 28.23%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 767.53%. Given that VolitionRX Ltd. has higher upside potential than Viridian Therapeutics, Inc., analysts believe VolitionRX Ltd. is more attractive than Viridian Therapeutics, Inc..

Viridian Therapeutics, Inc. has a beta of 0.914, which suggesting that the stock is 8.612% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. Viridian Therapeutics, Inc.'s net income of -$34.6M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 36.73x versus 20.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -49.03% compared to Viridian Therapeutics, Inc.'s net margin of 3.93%. Viridian Therapeutics, Inc.'s return on equity of -47.79% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

Viridian Therapeutics, Inc. has a consensus price target of $39.81, signalling upside risk potential of 28.23%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 143.51%. Given that Xtant Medical Holdings, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than Viridian Therapeutics, Inc..

Viridian Therapeutics, Inc. has a beta of 0.914, which suggesting that the stock is 8.612% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

Viridian Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Viridian Therapeutics, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

Viridian Therapeutics, Inc. quarterly revenues are $70.6M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Viridian Therapeutics, Inc.'s net income of -$34.6M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Viridian Therapeutics, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Viridian Therapeutics, Inc. is 36.73x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.